Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

Triple approval for Novartis in Japan

January 20, 2010
Sales and Marketing Afinitor, Asia, Exforge, Galvus, Japan, Novartis, hypertension

Japanese regulators have approved three new Novartis medicines for use patients with type II diabetes, high blood pressure and advanced …

News
Roche's cancer testing answers website

Digital Pharma: Byte-sized roundup

January 15, 2010
Medical Communications Diagnostics, Novartis, Roche, digital pharma, malaria

In this week’s roundup: Roche answers cancer testing questions, Novartis uses SMS in fight against malaria, UCB goes to Facebook …

News

Novartis launches Ilaris in the UK

January 12, 2010
Sales and Marketing Ilaris, Novartis, cryopyrin-associated periodic syndrome

Novartis has launched its new biologic Ilaris in the UK as a treatment for cryopyrin-associated periodic syndrome. The rare debilitating …

News

Alcon directors protest Novartis takeover bid

January 6, 2010
Research and Development, Sales and Marketing Alcon, Novartis

An independent committee of directors of Alcon has expressed its disappointment with the recent takeover bid from Novartis, saying the …

News

Novartis to acquire majority stake in Alcon

January 5, 2010
Sales and Marketing Alcon, Novartis, eye care

Novartis plans to gain a majority hold of global eye care leader Alcon, significantly boosting its presence in the sector. …

News

Pharma mergers and acquisitions in 2009

December 22, 2009
Research and Development, Sales and Marketing Abbott, GSK, J&J, JJ, M&A, MA, Novartis, Pfizer, Wyeth, generics, industry, merger, year in review

This year saw two ‘mega mergers’ in the sector, the acquisition of Wyeth by Pfizer and the reverse takeover of …

Feature
Novartislr

Novartis’ COPD contender cleared in EU

December 4, 2009
Sales and Marketing COPD, Novartis, resp

 Novartis has been given a green light in the European Union to sell its Onbrez respiratory drug, allowing the firm …

News

Incyte’s Novartis cancer drug deal could be worth $1bn

December 1, 2009
Research and Development Incyte, Novartis

Novartis has paid Incyte Corporation $150 million up front for the rights to two oral investigational hematology-oncology therapies.The first is …

News

Novartis opens $1bn flu vaccine plant

November 25, 2009
Manufacturing and Production Novartis, US, vaccines

Novartis has opened a new $1 billion vaccine manufacturing plant that is the first to be set up as a …

News

Novartis gets German OK for swine flu vaccine

November 5, 2009
Research and Development, Sales and Marketing Novartis, h1n1

 Novartis’ swine flu vaccine Celtura has been approved in Germany, its first market, in what is a major milestone for …

News

European approval for 3-in-1 version of Exforge

October 23, 2009
Sales and Marketing Diovan, Exforge, Novartis, cv, hypertension

European regulators have approved an expanded version of Novartis’ high blood pressure treatment Exforge.Exforge was first approved in Europe in …

News

New 2-in-1 Valturna outperforms Diovan

October 1, 2009
Sales and Marketing Diovan, Novartis, Tekturna, cv, hyp, hypertension

Novartis has gained US approval for a combination of its blockbuster blood pressure drug Diovan and its follow-up product Tekturna/Rasilez.Valturna …

News

Europe approves two swine-flu vaccines

September 30, 2009
Sales and Marketing EU, GSK, Novartis, h1n1

The European Commission has approved the use of two vaccines for the pandemic H1N1 virus, commonly known as swine flu. …

News

Daniel Vasella, chief executive and chairman Novartis

September 17, 2009
Sales and Marketing Novartis, Vasella

Feature

Novartis swine-flu jab effective in single dose

September 3, 2009
Manufacturing and Production, Research and Development, Sales and Marketing Novartis, h1n1

A study of Novartis' pandemic swine-flu jab shows it is potentially protective after just one dose, which could help eke …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025